Table 1.

Patient demographics of SMA children (n = 16) treated with onasemnogene abeparvovec.

ID	Sex	Earlier Treatment (Age in Years), Type of Treatment	Onasemnogene Abeparvovec Age (Years)	SMA Type	SMN2 Gene Copies	Ambulation Status at the Time of Imaging	Age at Imaging (Years)
1	F	0.2, Nusinersen	0.2	1	2	non-ambulatory	1.6
2	F	0.1, Nusinersen	0.2	1	2	non-ambulatory	1.4
3	M	0.2, Risdiplam	0.3	1	2	non-ambulatory	1.1
4	F		0.3	1	2	non-ambulatory	1.5
5	F		0.7	1	2	non-ambulatory	1.6
6	F	0.5, Nusinersen	0.9	1	2	non-ambulatory	2.2
7	M	0.5, Nusinersem	1.3	1	2	non-ambulatory	2.3
8	M	0.4, Nusinersen	1.3	1	2	non-ambulatory	3.7
9	M	0.3, Nusinersen	1.4	1	2	non-ambulatory	3.5
10	M		1.5	2	3	non-ambulatory	3.6
11	M	1.3, Nusinersen	1.5	2	3	minimal ambulatory	4.0
12	M	-, Risdiplam	1.5	1	3	ambulatory	1.6
13	M	0.2, Nusinersen	1.7	1	2	non-ambulatory	5.6
14	M	1.6, Nusinersen	3.3	2	3	non-ambulatory	4.8
15	F		3.7	1	2	non-ambulatory	4.3
16	F		4.9	2	3	non-ambulatory	6.9